Experimental Once-Monthly HIV Prevention Pill Shows Promise in Early Research
Pharmaceutical company Merck has announced an early global access strategy for Alimatravir (MK-8527), an experimental once-monthly pill being developed to help prevent HIV infection.
If approved by regulators, the company says it plans to make the medication available as quickly and affordably as possible in low- and middle-income countries through partnerships with generic drug manufacturers.
Designed as a Once-Monthly HIV Prevention Option
Alimatravir is being studied as an oral pre-exposure prophylaxis (PrEP) medication for the prevention of HIV-1.
Unlike many currently available oral PrEP medications that are taken daily, Alimatravir is designed to be taken once every month, which researchers hope could improve convenience and medication adherence.
Currently Being Evaluated in Clinical Trials
The experimental medicine is undergoing evaluation in two international Phase 3 clinical trials:
- EXPrESSIVE-10, conducted in partnership with the Gates Foundation, is assessing the safety and effectiveness of the drug among women and adolescent girls in sub-Saharan Africa.
- EXPrESSIVE-11 is enrolling participants across 16 countries who may have an increased likelihood of HIV exposure.
The studies are intended to evaluate the drug’s safety, effectiveness, and overall performance before any regulatory approval is considered.
Early Findings Are Encouraging
According to preliminary research, Alimatravir may begin working shortly after it is taken and could provide protection for approximately one month.
Researchers are also studying whether the medication maintains protective drug levels for a short period beyond the scheduled monthly dose, which could offer additional flexibility if a dose is delayed.
These findings remain under investigation and will require confirmation through ongoing clinical trials.
Merck Signs Agreements With Generic Manufacturers
Ahead of potential regulatory approval, Merck has signed royalty-free licensing agreements with seven generic pharmaceutical manufacturers.
Under these agreements, participating manufacturers would be permitted to produce and distribute Alimatravir in 129 low- and lower-middle-income countries, subject to regulatory approval.
The participating companies include manufacturers based in sub-Saharan Africa and India, reflecting an effort to expand future access in regions with a high burden of HIV.
Expanding Access to HIV Prevention
According to global health estimates, millions of people worldwide continue to live with HIV, with a significant proportion residing in sub-Saharan Africa.
If approved, a once-monthly oral prevention option could provide an additional choice for individuals who may find it challenging to follow a daily medication schedule.
Regulatory Review Still Pending
Merck expects results from the ongoing clinical trials in the second half of next year.
The company has also stated that it is expanding manufacturing capacity in preparation for potential future demand if the medication receives approval from health authorities.
As Alimatravir remains an investigational medicine, it has not yet been approved for public use. Its safety and effectiveness will continue to be evaluated through clinical research and regulatory review before it becomes available.
